Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDP791 plus carboplatin/paclitaxel in advanced non-squamous non-small-cell lung cancer
2005-001731-30Phase 2Completed
- Sponsor
- UCB
- Start
- May 2005
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alacizumab pegol in non-small cell lung cancer (NSCLC) (5 arms), sponsored by UCB. Primary endpoints: Tumor response rate and Safety and tolerability. Started May 2005; status: completed.
02
Drugs
alacizumab pegol
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-001731-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001731-30.